×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Pemphigus Market Share

ID: MRFR/Pharma/5024-HCR
100 Pages
Rahul Gotadki
October 2025

Pemphigus Market Research Report Information  By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Pemphigus Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Pemphigus Market Share Analysis

The Pemphigus market, a sector that is situated within dermatology and autoimmune disorders, has in place many strategic moves to attain competitive position as well as tackling the unique challenges of this autoimmune blistering disease. The central strategy is therapeutic innovation, where companies spend heavily on research and development to come up with advanced treatments for Pemphigus. These novel treatment options focus on enhancing patient’s lives, reducing side effects and better management of the disease. Companies therefore aim at introducing fresh solutions into the market so that they will be different from others and take advantage of large share of Pemphigus treatment market.

Pricing strategies play a crucial role in determining market share positioning in the Pemphigus segment. Given the long-term nature of autoimmune diseases as well as need for long-term treatment, different pricing models are usually adopted by companies. Some may choose to have competitive pricing which makes their therapies more affordable by a broader population. On the other hand, others use value-based pricing where they highlight specific advantages or innovative qualities present in their lines of treatment compared to other medications used in addressing Pemphigus thus justifying higher costs imposed on them. It is important to find an equilibrium between affordability and perceived worthiness so that patients can still have access to viable treatments while providing support for R&D sustainability.

Success in the Pemphigus market hinges on collaborations and partnerships. Such alliances are formed by firms so as to engage skin experts, people who deal with autoimmunity conditions together with research institutions helping them navigate through complexities surrounding development of pemphigus related treatments. Consequently, joint activities hasten clinical trials allowing improved production protocols; hence a strong distribution network is achieved making these firms key players in the pemphigus treatment market.

Marketing and branding strategies influence significantly market share within this industry segment. They engage themselves into extensive marketing campaigns aimed at addressing advantages offered by their Pemphigus treatment, creating awareness among dermatologists and health care professionals and building trust in their safety and efficacy. Presence in the market is created by use of educational projects, online platforms and participation on dermatology conferences thus influencing market share in a competitive landscape.

In terms of strategic considerations for companies aiming to consolidate their market share in the Pemphigus treatment sector, geographical expansion becomes important. Identifying regions with high prevalence rates of Pemphigus and designing strategies that are responsive to various regional healthcare needs become imperative. Customizing products, distribution channels and marketing approaches that are suitable for different cultural norms as well as regulatory frameworks enable effective entry into various parts of the world hence complete global presence.

As such, continued investment in post-market surveillance systems, pharmacovigilance activities as well as patient support programs is crucial for retaining as well as increasing market share in pemphigus treatment market. Proactively monitoring safety and effectiveness of treatments together with extensive education programs for patients ultimately helps to build trust between health practitioners with this particular category of sufferers. This long-term dedication towards patient wellness guarantees company’s achievement within the marketplace; as this indicates corporate social responsibility irrespective whether they are pemphigus stakeholders or not.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is Pemphigus?

Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

What is the CAGR of the Pemphigus Market?

The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

What is the major driver for the Pemphigus Market?

The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

Which is the leading regional Pemphigus Market?

Americas are anticipated to dominate the global Pemphigus Market.

What are the leading Pemphigus Market players?

Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

Market Summary

The Global Pemphigus Market is projected to grow from 1.67 USD Billion in 2024 to 4.0 USD Billion by 2035, reflecting a robust growth trajectory.

Key Market Trends & Highlights

Global Pemphigus Market Key Trends and Highlights

  • The market is expected to expand at a compound annual growth rate (CAGR) of 8.25 percent from 2025 to 2035.
  • By 2035, the market valuation is anticipated to reach 4.0 USD Billion, indicating substantial growth potential.
  • In 2024, the market is valued at 1.67 USD Billion, laying a strong foundation for future expansion.
  • Growing adoption of innovative treatment options due to increasing prevalence of pemphigus is a major market driver.

Market Size & Forecast

2024 Market Size 1.67 (USD Billion)
2035 Market Size 4.0 (USD Billion)
CAGR (2025-2035) 8.25%
Largest Regional Market Share in 2024 latin_america)

Major Players

Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc, Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries

Market Trends

Pemphigus Market Market Drivers

Market Growth Projections

The Global Pemphigus Market Industry is projected to experience substantial growth over the coming years. With a market value of 1.67 USD Billion in 2024, it is anticipated to reach 4.0 USD Billion by 2035. This growth trajectory reflects a CAGR of 8.25% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in treatment modalities, and increased research activities. The market's expansion indicates a growing recognition of pemphigus as a significant health concern, necessitating ongoing investment in therapeutic development and patient care.

Rising Incidence of Pemphigus

The Global Pemphigus Market Industry experiences a notable increase in the incidence of pemphigus, an autoimmune blistering disorder. Recent data suggests that the prevalence of pemphigus vulgaris is approximately 0.5 to 3 cases per 100,000 individuals globally. This rising incidence is likely to drive the demand for effective treatment options, contributing to the market's growth. As the population ages and awareness of autoimmune diseases increases, the Global Pemphigus Market Industry is projected to reach 1.67 USD Billion in 2024, indicating a strong need for innovative therapies and management strategies.

Supportive Government Policies

Supportive government policies and initiatives play a pivotal role in the Global Pemphigus Market Industry. Regulatory agencies are increasingly recognizing the need for effective treatments for rare diseases, including pemphigus. Policies that promote research funding, expedite drug approvals, and provide incentives for pharmaceutical companies are likely to foster innovation in this field. Such supportive measures can enhance the availability of treatment options, ultimately benefiting patients. As the market evolves, these policies may contribute to a more robust Global Pemphigus Market Industry, ensuring that patients have access to necessary therapies.

Growing Awareness and Education

Growing awareness and education regarding pemphigus among healthcare professionals and patients contribute positively to the Global Pemphigus Market Industry. Initiatives by health organizations and patient advocacy groups aim to disseminate information about the disease, its symptoms, and treatment options. This increased awareness is likely to facilitate early diagnosis and prompt treatment, thereby improving patient outcomes. As more individuals seek medical attention, the demand for therapies is expected to rise, further propelling the Global Pemphigus Market Industry's growth trajectory.

Advancements in Treatment Modalities

Innovations in treatment modalities significantly influence the Global Pemphigus Market Industry. The introduction of biologics and targeted therapies has transformed the management of pemphigus, offering improved efficacy and safety profiles. For instance, monoclonal antibodies such as rituximab have shown promising results in clinical trials, leading to increased adoption in clinical practice. This trend is expected to continue, with the market projected to expand at a CAGR of 8.25% from 2025 to 2035. As new therapies emerge, the Global Pemphigus Market Industry is likely to witness substantial growth, enhancing patient outcomes and quality of life.

Increased Research and Development Activities

The Global Pemphigus Market Industry benefits from heightened research and development activities aimed at understanding the pathophysiology of pemphigus. Government and academic institutions are increasingly investing in studies to identify novel therapeutic targets and biomarkers. This surge in R&D is anticipated to lead to the discovery of new treatment options, thereby expanding the market. With a projected market value of 4.0 USD Billion by 2035, the emphasis on innovation and scientific exploration is likely to play a crucial role in shaping the future of the Global Pemphigus Market Industry.

Market Segment Insights

Regional Insights

Key Companies in the Pemphigus Market market include

Industry Developments

  • Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Market Vulgaris Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company.
  • Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Market Vulgaris Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel cell therapy candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris.
  • Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Market Vulgaris Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris.
  • Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Market Vulgaris Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions.
  • Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Market Programs Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris.
  • Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Market Vulgaris Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development.
  • Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris.
  • Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Market Vulgaris Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China.
  • Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Market Vulgaris Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results.
  • Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Market Clinical Programs Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris.

Global Pemphigus Market, by Pemphigus Market Types

  • Pemphigus Market Vulgaris
  • Pemphigus Market Foliaceus
  • Pemphigus Market Vegetans
  • Paraneoplastic Pemphigus Market

Global Pemphigus Market, by Diagnosis

  • Skin peeling
  • Skin biopsy
  • Run blood tests
  • Endoscopy

Global Pemphigus Market, by Treatment

  • Initial therapy
  • Maintenance therapy
  • Immunosuppressants
  • Biological therapies
  • Intravenous Immunoglobulin (IVIG) therapy
  • Other medication

Global Pemphigus Market, by End User

  • Laboratories
  • Hospitals and Clinics
  • Academic and Research Institutes

Global Pemphigus Market, by Region

  • Americas
  • North America
  • US
  • Canada
  • South America
  • Europe
  • Western Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Rest of Western Europe
  • Eastern Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Republic of Korea
  • Rest of Asia Pacific
  • Middle East & Africa
  • Middle East
  • Africa

Future Outlook

Pemphigus Market Future Outlook

The Global Pemphigus Market is projected to grow at an 8.25% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing awareness, and rising healthcare expenditure.

New opportunities lie in:

  • Develop targeted therapies leveraging genetic research to improve treatment efficacy.
  • Expand telemedicine services for remote patient monitoring and management.
  • Invest in educational initiatives to raise awareness and early diagnosis of pemphigus.

By 2035, the Global Pemphigus Market is expected to achieve substantial growth, enhancing treatment accessibility and patient outcomes.

Market Segmentation

Report Overview

Pemphigus Market Industry Developments
  • {"Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris"=>[]}
  • {"Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris"=>[]}
  • {"Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris"=>[]}
  • {"Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris"=>[]}
  • {"Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs"=>[]}
  • {"Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris"=>[]}
  • {"Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline"=>[]}
  • {"Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris"=>[]}
  • {"Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris"=>[]}
  • {"Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs"=>[]}

Global Pemphigus Market Segmentation 

Report Scope

Report Attribute/Metric Details
  Market Size (2032)   3.21 Billion
  CAGR   7.57%
  Base Year   2022
  Forecast Period   2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered  Types, Diagnosis, Treatment, And End Users
  Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors  Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc., Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries.
  Key Market Opportunities · Healthcare expenditure · Research and development
  Key Market Drivers · Increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle · Increasing geriatric population and increasing awareness for oral hygiene

FAQs

What is Pemphigus?

Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

What is the CAGR of the Pemphigus Market?

The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

What is the major driver for the Pemphigus Market?

The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

Which is the leading regional Pemphigus Market?

Americas are anticipated to dominate the global Pemphigus Market.

What are the leading Pemphigus Market players?

Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

  1. Definition
  2. Research
  3. Assumptions
  4. Limitations
  5. Research Methodology
    1. Introduction
    2. Primary Research
    3. Secondary Research
    4. Market Size
    5. Estimation
    6. Chapter 4. Market Dynamics
    7. Drivers
    8. Restraints
    9. Opportunities
    10. Challenges
    11. Macroeconomic Indicators
    12. Technology
    13. Trends & Assessment
    14. Chapter 5. Market Factor Analysis
    15. Porter’s Five Forces Analysis
      1. Bargaining
      2. Threat of New Entrants
      3. Threat of Substitutes
      4. Intensity of Rivalry
    16. Bargaining Power of Suppliers
    17. Power of Buyers
    18. Value Chain Analysis
    19. Investment Feasibility Analysis
    20. Pricing Analysis
    21. Chapter 6. Global
  6. Pemphigus Market, by Pemphigus Types
    1. Introduction
    2. Pemphigus Vulgaris
    3. Market Estimates &
    4. Forecast, by Region, 2020–2027
    5. Market Estimates &
    6. Forecast, by Country, 2020–2027
    7. Pemphigus Foliaceus
  7. Market Estimates & Forecast, by Region, 2020–2027
  8. Market Estimates & Forecast, by Country, 2020–2027
    1. Pemphigus Vegetans
  9. Market Estimates & Forecast, by Region, 2020–2027
  10. Market Estimates & Forecast, by Country, 2020–2027
    1. Paraneoplastic Pemphigus
    2. Market Estimates & Forecast,
    3. by Region, 2020–2027
    4. Market Estimates & Forecast,
    5. by Country, 2020–2027
    6. Chapter 7. Global Pemphigus Market,
    7. by Diagnosis
    8. Introduction
    9. Skin Peeling
  11. Market Estimates & Forecast, by Region, 2020–2027
    1. Market Estimates & Forecast,
    2. by Country, 2020–2027
    3. Skin Biopsy
    4. Market Estimates
    5. & Forecast, by Region, 2020–2027
  12. Market Estimates & Forecast, by Country, 2020–2027
    1. Run Blood Tests
  13. Market Estimates & Forecast, by Region, 2020–2027
    1. Market Estimates & Forecast,
    2. by Country, 2020–2027
    3. Endoscopy
  14. Market Estimates & Forecast, by Region, 2020–2027
    1. Market Estimates & Forecast,
    2. by Country, 2020–2027
    3. Chapter 8. Global
  15. Pemphigus Market, by Treatment
    1. Introduction
    2. Corticosteroids
  16. Market Estimates & Forecast, by Region, 2020–2027
  17. Market Estimates & Forecast, by Country, 2020–2027
    1. Initial Therapy
  18. Market Estimates & Forecast, by Region, 2020–2027
  19. Market Estimates & Forecast, by Country, 2020–2027
    1. Maintenance Therapy
  20. Market Estimates & Forecast, by Region, 2020–2027
  21. Market Estimates & Forecast, by Country, 2020–2027
    1. Immunosuppressants
  22. Market Estimates & Forecast, by Region, 2020–2027
  23. Market Estimates & Forecast, by Country, 2020–2027
    1. Biological Therapies
  24. Market Estimates & Forecast, by Region,
  25. Market Estimates & Forecast, by Country, 2020–2027
    1. Intravenous Immunoglobulin (IVIG) Therapy
    2. Market Estimates
    3. & Forecast, by Region, 2020–2027
    4. Market Estimates & Forecast,
    5. by Country, 2020–2027
    6. Other medication
    7. Market
    8. Estimates & Forecast, by Region, 2020–2027
    9. Market Estimates &
    10. Forecast, by Country, 2020–2027
    11. Chapter 9. Global Pemphigus
  26. Market, by End User
    1. Introduction
    2. Laboratories
  27. Market Estimates & Forecast, by Region, 2020–2027
  28. Market Estimates & Forecast, by Country, 2020–2027
    1. Hospitals and Clinics
  29. Market Estimates & Forecast, by Region, 2020–2027
  30. Market Estimates & Forecast, by Country, 2020–2027
    1. Academic and Research Institutes
    2. Market Estimates & Forecast, by
    3. Region, 2020–2027
  31. Market Estimates & Forecast, by Country, 2020–2027
  32. Chapter 10. Global Pemphigus Market, by Region
    1. Introduction
    2. Americas
    3. North America
    4. Canada
    5. Spain
    6. of Western Europe
    7. Asia-Pacific
    8. South Korea
    9. Middle East & Africa
    10. Africa
    11. Chapter 11. Company Landscape
    12. Share Analysis
    13. Strategies
    14. Chapter 12. Company Profiles
    15. Company Overview
    16. Overview
    17. SWOT Analysis
    18. Roche
    19. Product Overview
    20. Overview
    21. Principia Biopharma, Inc
    22. Financial Overview
    23. Argenx
    24. Financial Overview
    25. Sanofi S.A.
    26. Financial overview
    27. Financial Overview
    28. Financial Overview
    29. GlaxoSmithKline LLC
    30. SWOT Analysis
    31. Overview
    32. SWOT Analysis
    33. Chapter 13 MRFR Conclusion
    34. From CEO’s Viewpoint
    35. Needs of the Market
    36. to Watch
    37. Industry
    38. Chapter 14. Appendix
    39.  
    40. LIST
  33. US
  34. South America
    1. Europe
      1. Western Europe
      2. Eastern Europe
      3. Japan
      4. China
      5. India
      6. Australia
      7. Rest of Asia-Pacific
      8. Middle East
    2. Introduction
    3. Market
    4. Key Development &
    5. Novartis Pharmaceuticals
      1. Product
      2. Financials Overview
      3. Key Developments
    6. Hoffmann-La
      1. Company Overview
      2. Financial
      3. Key Developments
      4. SWOT Analysis
      5. Company Overview
      6. Product Overview
      7. Key Development
      8. SWOT Analysis
      9. Company Overview
      10. Product Overview
      11. Key Development
      12. SWOT Analysis
      13. Company Overview
      14. Product Overview
      15. Key Developments
      16. SWOT Analysis
    7. Pfizer Inc
      1. Company Overview
      2. Product Overview
      3. Key Developments
      4. SWOT Analysis
    8. Teligent Inc
      1. Overview
      2. Product Overview
      3. Key Developments
      4. SWOT Analysis
      5. Overview
      6. Product Overview
      7. Financials
      8. Key Developments
    9. Teva Pharmaceutical Industries
      1. Overview
      2. Product
      3. Financials
      4. Key Developments
    10. Key Findings
      1. Unmet
    11. Key Companies
    12. Predictions for the Pemphigus
  35. OF TABLES
  36. Global Pemphigus Market
    1. Synopsis, 2020–2027
  37. Global
    1. Pemphigus Market Estimates and Forecast, 2020–2027
    2. (USD Million)
    3. Table 3
  38. Global Pemphigus Market, by Region, 2020–2027 (USD Million)
    1. Table
  39. Global Pemphigus Market, by Pemphigus Types,
    1. Table 5
  40. Global Pemphigus Market, by Diagnosis, 2020–2027(USD Million)
    1. Table
  41. Global Pemphigus Market, by Treatment, 2020–2027
    1. (USD Million)
  42. Global Pemphigus
  43. Market, by End User, 2020–2027 (USD Million)
    1. Table 8
  44. North America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  45. North America:
  46. Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
    1. Table 10
  47. North America: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  48. North America: Pemphigus Market,
    1. by End-User, 2020–2027 (USD Million)
  49. US:
  50. Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
    1. Table 13
  51. US: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
    1. Table
  52. US: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  53. US: Pemphigus Market, by End User, 2020–2027
    1. (USD Million)
  54. Canada: Pemphigus Market, by Pemphigus
    1. Types, 2020–2027 (USD Million)
  55. Canada: Pemphigus
  56. Market, by Diagnosis, 2020–2027 (USD Million)
  57. Canada:
  58. Pemphigus Market, by Treatment, 2020–2027 (USD Million)
    1. Table 19
  59. Canada: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  60. South
  61. America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  62. South America: Pemphigus Market, by Diagnosis,
  63. South America:
  64. Pemphigus Market, by Treatment, 2020–2027 (USD Million)
    1. Table 23
  65. South America: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  66. Europe: Pemphigus Market, by Pemphigus Types, 2020–2027
    1. (USD Million)
  67. Europe: Pemphigus Market, by Diagnosis,
    1. Table 26
  68. Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  69. Europe: Pemphigus Market, by End-User, 2020–2027
    1. (USD Million)
  70. Western Europe: Pemphigus Market,
    1. by Pemphigus Types, 2020–2027 (USD
    2. Million)
    3. Table
  71. Western Europe: Pemphigus Market, by Diagnosis, 2020–2027
    1. (USD Million)
  72. Western Europe: Pemphigus Market,
    1. by Treatment, 2020–2027 (USD Million)
    2. Table 31
  73. Western Europe: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  74. Eastern Europe: Pemphigus Market, by Pemphigus
    1. Types, 2020–2027 (USD
    2. Million)
    3. Table 33
  75. Eastern Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  76. Eastern Europe: Pemphigus Market, by Treatment,
  77. Eastern
  78. Europe: Pemphigus Market, by End-User, 2020–2027(USD Million)
  79. Asia-Pacific: Pemphigus Market, by Pemphigus Types,
    1. Million)
    2. Table 37
  80. Asia-Pacific: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  81. Asia-Pacific: Pemphigus Market, by Treatment, 2020–2027
    1. (USD Million)
  82. Asia-Pacific: Pemphigus Market, by End-User,
  83. Middle East &
  84. Africa: Pemphigus Market, by Pemphigus Types, 2020–2027
    1. (USD Million)
  85. Middle East & Africa:
  86. Pemphigus Market, by Technology, 2020–2027 (USD Million)
    1. Table
  87. Middle East & Africa: Pemphigus Market, by Treatment, 2020–2027
    1. (USD Million)
  88. Middle East & Africa: Pemphigus
  89. Market, by End-User, 2020–2027 (USD Million)
  90. LIST OF FIGURES
  91. Research Process
  92. Segmentation
    1. for Global Pemphigus Market
  93. Segmentation Market
    1. Dynamics for Global Pemphigus Market
  94. Global Pemphigus
  95. Market Share, By Pemphigus Types, 2020
  96. Global Pemphigus
  97. Market Share, By Diagnosis, 2020
  98. Global Pemphigus
  99. Market Share, By Treatment, 2020
  100. Global Pemphigus
  101. Market Share, By End User, 2020
  102. Global Pemphigus
  103. Market Share, By Region, 2020
  104. North America: Pemphigus
  105. Market Share, By Country, 2020
  106. Europe: Pemphigus
  107. Market Share, By Country, 2020
  108. Asia-Pacific: Pemphigus
  109. Market Share, By Country, 2020
  110. Middle East &
  111. Africa: Pemphigus Market Share, By Country, 2020
  112. Global
    1. Pemphigus Market: Company Share Analysis, 2020 (%)
    2. Figure 14
    3. Novartis Pharmaceuticals.: Key Financials
  113. Novartis
    1. Pharmaceuticals.: Segmental Revenue
    2. Figure 16
    3. Novartis Pharmaceuticals.: Geographical Revenue
    4. Figure 17
    5. Hoffmann-La Roche.: Key Financials
  114. Hoffmann-La
    1. Roche.: Segmental Revenue
  115. Hoffmann-La Roche.: Geographical
    1. Revenue
  116. Principia Biopharma, Inc.: Key Financials
  117. Principia Biopharma, Inc.: Segmental Revenue
    1. Figure
  118. Principia Biopharma, Inc.: Geographical Revenue
    1. Figure
  119. Argenx: Key Financials
  120. Argenx:
    1. Segmental Revenue
  121. Argenx: Geographical Revenue
  122. Sanofi S.A.: Key Financials
    1. Figure 27
    2. Sanofi S.A.: Segmental Revenue
  123. Sanofi S.A.:
    1. Geographical Revenue
  124. Pfizer Inc: Key Financials
  125. Pfizer Inc: Segmental Revenue
    1. Figure 31
    2. Pfizer Inc: Geographical Revenue
    3. Figure 32
    4. Teligent Inc: Key Financials
  126. Teligent Inc:
    1. Segmental Revenue
  127. Teligent Inc: Geographical Revenue
  128. GlaxoSmithKline LLC: Key Financials
    1. Figure 36
    2. GlaxoSmithKline LLC: Segmental Revenue
    3. Figure 37
    4. GlaxoSmithKline LLC: Geographical Revenue
  129. Teva
    1. Pharmaceutical Industries.: Key Financials
    2. Figure 39
    3. Teva Pharmaceutical Industries.: Segmental Revenue
    4. Figure 40
    5. Teva Pharmaceutical Industries.: Geographical Revenue

Pemphigus Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓